ArticleClinical rheumatology2025
Integrative GWAS and Mendelian randomization study of rheumatoid arthritis based on the 2019 UK Biobank questionnaire.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionRheumatoid arthritis (RA) is the most prevalent autoimmune inflammatory joint disorder worldwide. We aimed to identify the genetic variants contributing to RA and investigate the potential influence of related diseases on RA risk.
methodsWe performed genome-wide association studies (GWAS) on RA using the 2019 UK Biobank pain questionnaire. We conducted a primary GWAS (9,389 RA cases; 132,108 controls) and separate sex-stratified GWAS for females (4,832 cases; 75,184 controls) and males (4,557 cases; 56,924 controls). We incorporated 12 phenotypes from downstream analyses, such as genetic correlation analyses, transcriptome-wide association studies (TWAS), phenome-wide association studies (PheWAS), and Mendelian randomization (MR) studies to determine causal relationships with RA.
resultsTwo loci reached genome-wide significance in the primary GWAS. The top SNP, rs35139284 (p = 3.67 × 10
conclusionOur findings confirmed an RA locus at chromosome 6 and highlighted associations between RA and a spectrum of immune-related and inflammatory phenotypes. Further analyses may provide greater insights into the genetic architecture of RA. Key Points • Leveraging the 2019 UK Biobank pain questionnaire, our genome-wide association studies (GWAS) confirmed a risk locus on chromosome 6 associated with rheumatoid arthritis (RA). • Sex-stratified analyses revealed significant differences in RA susceptibility between males and females, paving the way for personalized therapeutic strategies by demonstrating sex-specific genetic risks. • Mendelian randomization underscored the associations of both asthma and eosinophils with RA while identifying key hub genes, thereby deepening our understanding of RA's underlying molecular mechanisms and suggesting potential targets for future interventions.
Indexed as
Identifiers
40762897What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.